You are here:

apixaban (Eliquis)

Advice

following a full submission:  

apixaban (Eliquis®) is accepted for use within NHS Scotland. 

Indication under review: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. 

In two large phase III double-blind comparative studies, in patients undergoing elective hip or knee replacement surgery, apixaban was superior to a low molecular weight heparin for the incidence of VTE and all cause death whilst incidence of major bleeding events was similar between groups. 

Drug Details

Drug Name: apixaban (Eliquis)
SMC Drug ID: 741/11
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd
Indication: For the treatment of venous thromboembolic events (VTE) in adult patients who have undergone elective hip (THR) or knee (TKR) replacement surgery.
BNF Category:
Submission Type: Full submission
Status: Accepted
Date Advice Published: 12 December 2011

Back